Since BRD4 has both metastasis inhibiting and metastasis enhancing capacities due to the opposing effects of the two isoforms [2,3], the effect of these inhibitors on long term survival in breast cancer patients remains unclear. Here, BRD4 is linked to breast carcinoma.